Yu JC, et al. – This study is planned to assess the lifetime cost–effectiveness of intermittent, reversible vagal nerve blocking (via the implantable weight loss device vBloc) therapy versus conventional therapy as treatment for patients who are class 2 obese with diabetes and for those who are class 3 obese with or without diabetes, who have found pharmacotherapy and behavioral therapies ineffective, but are not prepared or willing to undergo current bariatric surgical options. As per findings, vagal nerve blocking therapy seems a cost–effective alternative to conventional therapy in these patients.